<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Arch Med Sci</journal-id><journal-id journal-id-type="publisher-id">AMS</journal-id><journal-title-group><journal-title>Archives of Medical Science : AMS</journal-title></journal-title-group><issn pub-type="ppub">1734-1922</issn><issn pub-type="epub">1896-9151</issn><publisher><publisher-name>Termedia Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28721148</article-id><article-id pub-id-type="pmc">5510505</article-id><article-id pub-id-type="publisher-id">30080</article-id><article-id pub-id-type="doi">10.5114/aoms.2017.68142</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>Association of moderate aerobic exercise and rho-associated kinase 2 concentration in subjects with dyslipidemia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bai</surname><given-names>Huadong</given-names></name><xref ref-type="aff" rid="aff0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Jingchun</given-names></name><xref ref-type="aff" rid="aff0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Du</surname><given-names>Guiying</given-names></name><xref ref-type="aff" rid="aff0003">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jiao</surname><given-names>Fengjun</given-names></name><xref ref-type="aff" rid="aff0004">4</xref></contrib></contrib-group><aff id="aff0001"><label>1</label>Department of Cardiology, Zhengzhou Central Hospital, Zhengzhou, Henan Province, China</aff><aff id="aff0002"><label>2</label>Department of Cardiology, Shanxian Central Hospital, Heze, Shandong Province, China</aff><aff id="aff0003"><label>3</label>Department of Cardiology, People&#x02019;s Hospital of Lingcheng District, Dezhou, Shandong Province, China</aff><aff id="aff0004"><label>4</label>Department of Cardiology, The First People&#x02019;s Hospital of Xianyang, Xianyang, Shanxi, China</aff><author-notes><corresp id="cor1"><bold>Corresponding author:</bold> Fengjun Jiao, Department of Cardiology, The First People&#x02019;s Hospital of Xianyang, Fu No. 10, Biyuan Road, Xianyang, Shanxi Province, China, 712000. Phone: +86 29 33288218. Fax: +86 29 33288218. E-mail: <email xlink:href="jiaofengjun123@sina.com">jiaofengjun123@sina.com</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2017</year></pub-date><volume>13</volume><issue>4</issue><fpage>807</fpage><lpage>812</lpage><history><date date-type="received"><day>02</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>17</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2017 Termedia &#x00026; Banach</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.</license-p></license></permissions><abstract><sec id="s1"><title>Introduction</title><p>Dyslipidemia is associated with increased rho-associated kinase 2 (ROCK2) concentration. Whether moderate aerobic exercise could attenuate leukocyte ROCK2 concentration is unknown.</p></sec><sec id="s2"><title>Material and methods</title><p>One hundred subjects with dyslipidemia and without statin treatment were enrolled and assigned to exercise and control groups. In the exercise group, at least 30 min of moderate aerobic exercise per day 5 times weekly was recommended. In the control group, participants were recommended to undertake exercise of the same intensity as the exercise group but not mandatorily. At baseline and 3 months later, between-group differences were compared.</p></sec><sec id="s3"><title>Results</title><p>At baseline, dyslipidemia in both groups was characterized by increased serum levels of total cholesterol and low density lipoprotein cholesterol (LDL-C). Serum high-sensitivity C-reactive protein (hs-CRP) level was comparably increased too, and the average daily exercise time was extremely low: 5.8 &#x000b1;2.7 min and 6.2 &#x000b1;3.1 min respectively. Leukocyte ROCK2 concentration in the two groups was 38.4 &#x000b1;7.5 mg/ml and 40.2 &#x000b1;8.2 mg/ml respectively. Three months later, compared with the control group, average daily exercise time was significantly longer in the exercise group (37.4 &#x000b1;4.3 min vs. 16.5 &#x000b1;7.5 min, <italic>p</italic> &#x0003c; 0.05). Leukocyte ROCK2 concentration was also significantly reduced (27.6 &#x000b1;4.3 mg/ml vs. 34.6 &#x000b1;5.2 mg/ml, <italic>p</italic> &#x0003c; 0.05). Serum nitric oxide (NO) concentration in the exercise group was significantly higher than the control group (<italic>p</italic> &#x0003c; 0.05). Multivariate linear regression analysis revealed that NO and exercise time were significantly associated with leukocyte ROCK2 concentration after adjusting for traditional risk factors.</p></sec><sec id="s4"><title>Conclusions</title><p>Moderate aerobic exercise could effectively attenuate leukocyte ROCK2 concentration in subjects with dyslipidemia.</p></sec></abstract><kwd-group><kwd>dyslipidemia</kwd><kwd>aerobic exercise</kwd><kwd>rho-associated kinase</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Atherosclerosis is recognized as a chronic inflammatory disease which is mainly characterized by endothelial dysfunction [<xref rid="cit0001" ref-type="bibr">1</xref>, <xref rid="cit0002" ref-type="bibr">2</xref>]. Endothelial dysfunction, as defined by decreased generation of nitric oxide (NO), is known to contribute to increased endothelium permeability thereby enhancing leukocyte infiltration and accumulation within the vascular wall [<xref rid="cit0003" ref-type="bibr">3</xref>]. Previously, a substantial amount of studies have consistently revealed that in morbid conditions such as dyslipidemia, hypertension and diabetes mellitus, increased leukocyte rho-associated kinase (ROCK) concentration leads to the initiation and progression of atherosclerosis [<xref rid="cit0004" ref-type="bibr">4</xref>&#x02013;<xref rid="cit0006" ref-type="bibr">6</xref>], and the underlying mechanisms operating in these processes include ROCK&#x02019;s actions on increasing reactive oxygen species (ROS) generation and destabilizing endothelial nitric oxide synthase (eNOS) mRNA [<xref rid="cit0007" ref-type="bibr">7</xref>&#x02013;<xref rid="cit0009" ref-type="bibr">9</xref>]. Therefore, it is conceivable that reduced ROCK expression may confer cardiovascular benefits. Indeed, some experimental studies show that a ROCK inhibitor, fasudil or Y-27632, is beneficial for improving endothelial dysfunction, ameliorating oxidative stress and inflammatory reactions, which together contribute to improvement of cardiac remodeling and cardiac function [<xref rid="cit0010" ref-type="bibr">10</xref>&#x02013;<xref rid="cit0012" ref-type="bibr">12</xref>]. However, due to the lack of solid evidence, currently, no ROCK inhibitor has been approved for the treatment of atherosclerosis and atherosclerotic cardiovascular diseases (ASCVD).</p><p>At present, increasing moderate aerobic exercise is strongly recommended for the primary and secondary prevention of ASCVD [<xref rid="cit0013" ref-type="bibr">13</xref>&#x02013;<xref rid="cit0015" ref-type="bibr">15</xref>]. The mechanisms associated with clinical benefits derived from moderate aerobic exercise are partially due to its effects on improving cholesterol and glucose metabolism, which thereby improve endothelial function and inflammation [<xref rid="cit0014" ref-type="bibr">14</xref>&#x02013;<xref rid="cit0016" ref-type="bibr">16</xref>]. However, whether moderate aerobic exercise can attenuate leukocyte ROCK concentration has not been well studied yet.</p><p>With respect to the epidemic of dyslipidemia in the last decade, it is warranted to evaluate whether the most cost-effective element of lifestyle, that is moderate aerobic exercise, can improve dyslipidemia. Moreover, whether these benefits are related to ROCK reduction also deserved assessment. We therefore conducted a study to clarify whether moderate aerobic exercise is beneficial for reducing leukocyte ROCK2 (a significant isoform of the ROCK family) concentration in subjects with dyslipidemia.</p></sec><sec sec-type="material|methods" id="sec2"><title>Material and methods</title><sec id="sec2.1"><title>Study participants</title><p>One hundred participants with newly diagnosed dyslipidemia who had no history of ASCVD, hypertension, diabetes mellitus, or other liver, renal or rheumatic diseases were enrolled after oral informed consent was obtained. The present study was approved by the ethic committee of clinical research of the participating hospital. None of the participants had been treated with lipid-lowering treatment before. Initially, 100 participants were randomly assigned into the exercise group (<italic>n</italic> = 50), in whom at least 30 min of moderate aerobic exercise (in terms of fast walking or jogging) per day 5 times every week was strongly recommended and was monitored closely by the study investigators. The other 50 participants in the control group were also recommended to undertake exercise of the same intensity as subjects in the exercise group, but it was not mandatorily required and monitored closely. At baseline and 3 months later, demographic and biochemical variables were recorded by two working investigators and were re-checked by the third investigator. Fasting venous blood was drawn, and all the biochemical measurements were performed in the laboratory center of the participating hospital.</p></sec><sec id="sec2.2"><title>Measurement of serum NO concentration</title><p>Total NO was evaluated by the nitrite reductase method using the Total Nitric Oxide Kit (Beyotime Company, China, S0024). All the procedures were performed in accordance with the manufacturer&#x02019;s protocol. NO production at baseline and 3 months later was evaluated. Briefly, 10 ml of fasting venous blood was drawn and was quantified by the bicinchoninic acid (BCA) assay. Sodium nitrite (NaNO<sub>2</sub>) supplied within the Total Nitric Oxide Kit was used to determine the standard curve. Optical density of each sample was detected by an enzyme-labeling measuring instrument at a wavelength of 540 nm, and the concentration was determined from the standard curve. All the measurements were repeated 3 times to determine the arithmetic mean.</p></sec><sec id="sec2.3"><title>Leukocyte ROCK2 concentration assessment</title><p>Enzyme-linking immune-sorbent assay (ELISA kit, Abcam company, ab160505) was used to evaluate leukocyte ROCK2 concentration. Fasting venous samples were drawn and stored at &#x02013;80&#x000b0;C until use. All the procedures were in accordance with the manufacturer&#x02019;s instructions, and all the measurements were repeated 3 times to determine the arithmetic mean.</p></sec><sec id="sec2.4"><title>Statistical analysis</title><p>Continuous data were presented as mean &#x000b1; standard deviation (SD) or median (inter-quartile range) as appropriate, and were compared by the Student&#x02019;s <italic>t</italic>-test when data were normally distributed; otherwise they were compared by the Wilcoxon rank-sum test. Categorical data were presented as percentages and compared by &#x003c7;<sup>2</sup> test. Multivariate linear regression analysis was conducted to evaluate the relationship between exercise and other variables with the leukocyte ROCK2 concentration. All reported <italic>p</italic>-values were 2-sided, and a <italic>p</italic>-value of &#x0003c; 0.05 was considered statistically significant. All statistical analyses were conducted with the SPSS statistical package for Windows version 19.0 (SPSS Inc., Chicago, Illinois).</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><sec id="sec3.1"><title>Baseline characteristics of studied subjects</title><p>There was no significant difference in baseline characteristics between these two groups, as shown in <xref ref-type="table" rid="t0001">Table I</xref>. The ages of the two groups were 49.6 &#x000b1;6.3 and 48.3 &#x000b1;8.1 years, and subjects were predominantly male (72.0% vs. 70.0%). At baseline, both groups were characterized by increased serum levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), apoB100 and Lp(a) accompanied with decreased serum levels of high-density lipoprotein cholesterol (HDL-C) and apoA1. Of note, no significant differences in lipid profiles were observed. Serum high sensitivity C-reactive protein (hs-CRP) level was comparably increased in both groups, and the average daily exercise time of both groups was extremely low, at 5.8 &#x000b1;2.7 min and 6.2 &#x000b1;3.1 min, respectively. Leukocyte ROCK2 concentration in the two groups was 38.4 &#x000b1;7.5 mg/ml and 40.2 &#x000b1;8.2 mg/ml, respectively. Overall, no differences in baseline characteristics were observed between the two groups.</p><table-wrap id="t0001" position="float"><label>Table I</label><caption><p>Baseline characteristics comparisons</p></caption><table frame="border" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Exercise (<italic>n</italic> = 50)</th><th align="center" rowspan="1" colspan="1">Control (<italic>n</italic> = 50)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age [years]</td><td align="center" rowspan="1" colspan="1">49.6 &#x000b1;6.3</td><td align="center" rowspan="1" colspan="1">48.3 &#x000b1;8.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Male, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">36 (72.0)</td><td align="center" rowspan="1" colspan="1">35 (70.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI [kg/m<sup>2</sup>]</td><td align="center" rowspan="1" colspan="1">23.2 &#x000b1;3.5</td><td align="center" rowspan="1" colspan="1">23.8 &#x000b1;3.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">14 (28.0)</td><td align="center" rowspan="1" colspan="1">15 (30.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP [mm Hg]</td><td align="center" rowspan="1" colspan="1">118.2 &#x000b1;13.6</td><td align="center" rowspan="1" colspan="1">120.6 &#x000b1;11.5</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP [mm Hg]</td><td align="center" rowspan="1" colspan="1">73.6 &#x000b1;9.2</td><td align="center" rowspan="1" colspan="1">71.8 &#x000b1;9.7</td></tr><tr><td align="left" rowspan="1" colspan="1">HR [bpm]</td><td align="center" rowspan="1" colspan="1">75.4 &#x000b1;6.6</td><td align="center" rowspan="1" colspan="1">77.1 &#x000b1;5.5</td></tr><tr><td align="left" rowspan="1" colspan="1">TG [mmol/l]</td><td align="center" rowspan="1" colspan="1">1.4 &#x000b1;0.3</td><td align="center" rowspan="1" colspan="1">1.5 &#x000b1;0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">TC [mmol/l]</td><td align="center" rowspan="1" colspan="1">5.8 &#x000b1;0.3</td><td align="center" rowspan="1" colspan="1">5.8 &#x000b1;0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-C [mmol/l]</td><td align="center" rowspan="1" colspan="1">3.9 &#x000b1;0.4</td><td align="center" rowspan="1" colspan="1">3.8 &#x000b1;0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-C [mmol/l]</td><td align="center" rowspan="1" colspan="1">0.9 &#x000b1;0.2</td><td align="center" rowspan="1" colspan="1">0.9 &#x000b1;0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">apoA1 [mmol/l]</td><td align="center" rowspan="1" colspan="1">1.0 &#x000b1;0.3</td><td align="center" rowspan="1" colspan="1">1.0 &#x000b1;0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">apoB100 [mmol/l]</td><td align="center" rowspan="1" colspan="1">1.9 &#x000b1;0.2</td><td align="center" rowspan="1" colspan="1">2.0 &#x000b1;0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Lp(a) [mg/l]</td><td align="center" rowspan="1" colspan="1">132.4 &#x000b1;15.6</td><td align="center" rowspan="1" colspan="1">135.7 &#x000b1;17.3</td></tr><tr><td align="left" rowspan="1" colspan="1">FBG [mmol/l]</td><td align="center" rowspan="1" colspan="1">5.4 &#x000b1;0.5</td><td align="center" rowspan="1" colspan="1">5.6 &#x000b1;0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Cr [&#x000b5;mol/l]</td><td align="center" rowspan="1" colspan="1">93.3 &#x000b1;11.5</td><td align="center" rowspan="1" colspan="1">91.7 &#x000b1;9.4</td></tr><tr><td align="left" rowspan="1" colspan="1">BUN [mmol/l]</td><td align="center" rowspan="1" colspan="1">5.2 &#x000b1;1.0</td><td align="center" rowspan="1" colspan="1">5.4 &#x000b1;1.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Hs-CRP [mg/l]</td><td align="center" rowspan="1" colspan="1">4.5 &#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">4.6 &#x000b1;1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">ROCK2 concentration [mg/ml]</td><td align="center" rowspan="1" colspan="1">38.4 &#x000b1;7.5</td><td align="center" rowspan="1" colspan="1">40.2 &#x000b1;8.2</td></tr><tr><td align="left" rowspan="1" colspan="1">NO concentration [&#x000b5;mol/l]</td><td align="center" rowspan="1" colspan="1">8.3 &#x000b1;1.1</td><td align="center" rowspan="1" colspan="1">8.9 &#x000b1;1.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Average daily exercise time [min]</td><td align="center" rowspan="1" colspan="1">5.8 &#x000b1;2.7</td><td align="center" rowspan="1" colspan="1">6.2 &#x000b1;3.1</td></tr></tbody></table><table-wrap-foot><fn><p><italic>BMI &#x02013; body mass index, SBP &#x02013; systolic blood pressure, DBP &#x02013; diastolic blood pressure, HR &#x02013; heart rate (beats per m inute), TG &#x02013; triglyceride, TC &#x02013; total cholesterol, LDL-C &#x02013; low-density lipoprotein cholesterol, HDL-C &#x02013; high-density lipoprotein cholesterol, ApoA1 &#x02013; apoprotein A1, apoB100 &#x02013; apoprotein B100, Lp(a) &#x02013; lipoprotein (a), FBG &#x02013; fasting blood glucose, Cr &#x02013; creatinine, BUN &#x02013; blood urea nitrogen, Hs-CRP &#x02013; high-sensitivity C-reactive protein</italic>.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3.2"><title>Comparisons of characteristics after 3 months</title><p>Three months later, 42 participants in the exercise group had completed the exercise program in terms of at least 30 min of daily moderate aerobic exercise 5 times per week, and the other 8 participants who could not finish this program were excluded from the final analyses. Compared with the control group, the average daily exercise time was significantly longer in the exercise group (37.4 &#x000b1;4.3 min vs. 16.5 &#x000b1;7.5 min, <italic>p</italic> &#x0003c; 0.05), although exercise time in the control group was also increased compared to baseline (16.5 &#x000b1;7.5 min vs. 6.2 &#x000b1;3.1 min, <italic>p</italic> &#x0003c; 0.05). Leukocyte ROCK2 concentration was significantly lower in the exercise group compared with the control group (27.6 &#x000b1;4.3 mg/ml vs. 34.6 &#x000b1;5.2 mg/ml, <italic>p</italic> &#x0003c; 0.05). In addition, serum levels of LDL-C, HDL-C, Lp(a) and hs-CRP were also significantly lower in the exercise group (<italic>p</italic> &#x0003c; 0.05). Notably, as shown in <xref ref-type="table" rid="t0002">Table II</xref>, some variables such as smoking, serum Lp(a) and hs-CRP levels, and leukocyte ROCK2 concentration in the control group were slightly improved when compared with baseline.</p><table-wrap id="t0002" position="float"><label>Table II</label><caption><p>Comparisons of characteristics 3 months later</p></caption><table frame="border" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Exercise (<italic>n</italic> = 42)</th><th align="center" rowspan="1" colspan="1">Control (<italic>n</italic> = 50)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age [years]</td><td align="center" rowspan="1" colspan="1">50.4 &#x000b1;5.8</td><td align="center" rowspan="1" colspan="1">48.5 &#x000b1;5.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Male, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">31 (73.8)</td><td align="center" rowspan="1" colspan="1">35 (70.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI [kg/m<sup>2</sup>]</td><td align="center" rowspan="1" colspan="1">21.6 &#x000b1;2.4</td><td align="center" rowspan="1" colspan="1">23.5 &#x000b1;2.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">11 (26.2)</td><td align="center" rowspan="1" colspan="1">135 (26.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP [mm Hg]</td><td align="center" rowspan="1" colspan="1">113.8 &#x000b1;10.3</td><td align="center" rowspan="1" colspan="1">118.4 &#x000b1;10.7</td></tr><tr><td align="left" rowspan="1" colspan="1">DBP [mm Hg]</td><td align="center" rowspan="1" colspan="1">71.7 &#x000b1;7.9</td><td align="center" rowspan="1" colspan="1">72.0 &#x000b1;8.8</td></tr><tr><td align="left" rowspan="1" colspan="1">HR [bpm]</td><td align="center" rowspan="1" colspan="1">72.6 &#x000b1;5.4</td><td align="center" rowspan="1" colspan="1">76.2 &#x000b1;6.2</td></tr><tr><td align="left" rowspan="1" colspan="1">TG [mmol/l]</td><td align="center" rowspan="1" colspan="1">1.4 &#x000b1;0.3</td><td align="center" rowspan="1" colspan="1">1.6 &#x000b1;0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">TC [mmol/l]</td><td align="center" rowspan="1" colspan="1">5.3 &#x000b1;0.5</td><td align="center" rowspan="1" colspan="1">5.7 &#x000b1;0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-C [mmol/l]</td><td align="center" rowspan="1" colspan="1">3.1 &#x000b1;0.4<xref ref-type="table-fn" rid="tf2-1">*</xref></td><td align="center" rowspan="1" colspan="1">3.8 &#x000b1;0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL-C [mmol/l]</td><td align="center" rowspan="1" colspan="1">1.2 &#x000b1;0.3<xref ref-type="table-fn" rid="tf2-1">*</xref></td><td align="center" rowspan="1" colspan="1">0.9 &#x000b1;0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">apoA1 [mmol/l]</td><td align="center" rowspan="1" colspan="1">1.1 &#x000b1;0.2</td><td align="center" rowspan="1" colspan="1">0.9 &#x000b1;0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">apoB100 [mmol/l]</td><td align="center" rowspan="1" colspan="1">1.5 &#x000b1;0.3</td><td align="center" rowspan="1" colspan="1">2.0 &#x000b1;0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Lp(a) [mg/l]</td><td align="center" rowspan="1" colspan="1">104.6 &#x000b1;10.7<xref ref-type="table-fn" rid="tf2-1">*</xref></td><td align="center" rowspan="1" colspan="1">136.8 &#x000b1;18.9</td></tr><tr><td align="left" rowspan="1" colspan="1">FBG [mmol/l]</td><td align="center" rowspan="1" colspan="1">5.3 &#x000b1;0.4</td><td align="center" rowspan="1" colspan="1">5.6 &#x000b1;0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Cr [&#x000b5;mol/l]</td><td align="center" rowspan="1" colspan="1">94.1 &#x000b1;10.7</td><td align="center" rowspan="1" colspan="1">93.3 &#x000b1;9.0</td></tr><tr><td align="left" rowspan="1" colspan="1">BUN [mmol/l]</td><td align="center" rowspan="1" colspan="1">5.4 &#x000b1;1.1</td><td align="center" rowspan="1" colspan="1">5.5 &#x000b1;1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Hs-CRP [mg/l]</td><td align="center" rowspan="1" colspan="1">3.1 &#x000b1;1.2<xref ref-type="table-fn" rid="tf2-1">*</xref></td><td align="center" rowspan="1" colspan="1">4.4 &#x000b1;1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">ROCK2 concentration [mg/ml]</td><td align="center" rowspan="1" colspan="1">27.6 &#x000b1;4.3<xref ref-type="table-fn" rid="tf2-1">*</xref></td><td align="center" rowspan="1" colspan="1">34.6 &#x000b1;5.2</td></tr><tr><td align="left" rowspan="1" colspan="1">NO concentration [&#x000b5;mol/l]</td><td align="center" rowspan="1" colspan="1">12.2 &#x000b1;2.0</td><td align="center" rowspan="1" colspan="1">10.7 &#x000b1;1.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Average daily exercise time [min]</td><td align="center" rowspan="1" colspan="1">37.4 &#x000b1;4.3<xref ref-type="table-fn" rid="tf2-1">*</xref></td><td align="center" rowspan="1" colspan="1">16.5 &#x000b1;7.5</td></tr></tbody></table><table-wrap-foot><fn id="tf2-1"><label>*</label><p><italic>p &#x0003c; 0.05</italic>.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3.3"><title>Changes of serum NO concentration</title><p>At baseline, serum NO concentrations in the exercise (17.8 &#x000b1;2.6 &#x000b5;mol/l) and control groups (18.3 &#x000b1;3.1 &#x000b5;mol/l) were comparable. Nonetheless, 3 months later, serum NO concentration in the exercise group improved significantly more than that in the control group: 30.6 &#x000b1;4.5 &#x000b5;mol/l vs. 22.6 &#x000b1; 3.9 &#x000b5;mol/l (<italic>p</italic> &#x0003c; 0.05).</p></sec><sec id="sec3.4"><title>Relationship between exercise and other variables with leukocyte ROCK2 concentration</title><p>In order to investigate the association of the degree of exercise and other variables and leukocyte ROCK2 concentration, multivariate linear regression analysis was performed. After adjusting for age and gender (model 1), body mass index (BMI), smoking, LDL-C, Lp(a), hs-CRP, NO and exercise time were significantly associated with leukocyte ROCK2 concentration. After further adjusting for BMI, smoking, LDL-C and Lp(a) (model 2), only NO and exercise time remained significantly associated with leukocyte ROCK2 concentration, with an odds ratio of 0.825 (exercise group versus control group, 95% confidence interval (CI): 0.783&#x02013;0.866, <italic>p</italic> &#x0003c; 0.05) for NO and an odds ratio of 0.813 (exercise group versus control group, 95% CI: 0.748&#x02013;0.872, <italic>p</italic> &#x0003c; 0.05) for exercise time.</p></sec></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>Our preliminary research revealed that in subjects with dyslipidemia without previous lipid-lowering therapy, 3 months of moderate aerobic exercise is beneficial for dyslipidemia improvement. Furthermore, moderate aerobic exercise could attenuate leukocyte ROCK2 concentration and promote serum NO concentration. In addition, with respect to the clinical relevance, we consider that there is high cost-effectiveness of recommending moderate aerobic exercise in both dyslipidemic subjects and healthy populations for its potential benefits in reducing the incidence of cardiovascular diseases.</p><p>Notably, dyslipidemia is one of the major modifiable risk factors for atherosclerosis and ASCVD [<xref rid="cit0017" ref-type="bibr">17</xref>]. Through eliciting oxidative stress and inflammation, an increased serum cholesterol level impairs endothelial function and promotes leukocyte ROCK2 concentration, and that is the underlying mechanism by which statins confer their pleiotropic effects on the cardiovascular system [<xref rid="cit0018" ref-type="bibr">18</xref>]. In short, moderate aerobic exercise is beneficial for lipid lowering and endothelium protection [<xref rid="cit0019" ref-type="bibr">19</xref>]. However, whether the benefits derived from this kind of lifestyle modification is attributed to reduced leukocyte ROCK2 concentration has not been fully investigated yet. ROCK2 is known to be highly expressed in the cardiac muscle and vascular system. After being activated by Rho-GTPase, ROCK2 phosphorylates Ser<sup>19</sup> of myosin light chain and subsequently increases cellular contractility, impairs endothelial function, and enhances vascular smooth muscle cell migration and leukocyte infiltration [<xref rid="cit0020" ref-type="bibr">20</xref>]. Indeed, numerous previous studies have consistently revealed that increased leukocyte ROCK2 concentration is associated with atherosclerotic development. For example, Yoneda <italic>et al</italic>. found that rather than ROCK1-depleted cells, phagocytic uptake of fibronectin-coated beads is down-regulated in ROCK2-depleted cells [<xref rid="cit0021" ref-type="bibr">21</xref>]. In addition, Qian Zhou <italic>et al</italic>. reported that through inhibiting peroxisome proliferator-activated receptor-&#x003b3;-mediated reversal of cholesterol transport in macrophages, ROCK2 contributed to atherosclerosis development and progression [<xref rid="cit0022" ref-type="bibr">22</xref>]. Moreover, Okamoto <italic>et al</italic>. revealed that compared with wild type mice, cardiac-specific deletion of ROCK2 prevented cardiac hypertrophy as stimulated by angiotensin-II [<xref rid="cit0023" ref-type="bibr">23</xref>]. Despite compelling evidence indicating the close relationship between ROCK2 and cardiovascular diseases, no selective inhibitor for ROCK2 is currently approved for clinical application.</p><p>Interestingly and importantly, our present research revealed that short-term moderate aerobic exercise not only could modulate cholesterol metabolism but also could improve endothelial function and reduce leukocyte ROCK2 concentration. Indeed, many studies have indicated that moderate aerobic exercise is beneficial for cholesterol lowering and glucose regulation. In addition, moderate aerobic exercise augments tissue perfusion and reduces oxidative stress, which may lead to improvement of endothelial function. Nonetheless, whether these benefits of moderate aerobic exercise are associated with ROCK2 alteration is not fully clear yet. The results from our present research supported the notion that moderate aerobic exercise is beneficial for reduced leukocyte ROCK2 concentration. As shown in <xref ref-type="table" rid="t0002">Table II</xref>, the leukocyte ROCK2 concentrations were decreased in both groups after 3 months as compared with baseline, and it might be at least partially due to increased exercise time, and the fact that the magnitude of the decrease of leukocyte ROCK2 concentration was greater in the exercise group further supported this notion. Furthermore, multivariable linear regression analysis revealed that, after extensively adjusting for potential covariates, exercise time remained significantly associated with leukocyte ROCK2 concentration. With respect to the physiological effects of moderate aerobic exercise on the cardiovascular system, we considered that the following mechanisms might explain our findings. First, as mentioned above, moderate aerobic exercise is beneficial to augment tissue perfusion and thereby reduce oxidative stress [<xref rid="cit0013" ref-type="bibr">13</xref>]. Since oxidative stress could up-regulate leukocyte ROCK2 concentration, it was possible that through ameliorating oxidative stress, moderate aerobic exercise decreased leukocyte ROCK2 concentration. Second, since an increased cholesterol level is always accompanied by increased generation of isoprenoid intermediates, critical substrates for leukocyte ROCK2 concentration increased [<xref rid="cit0024" ref-type="bibr">24</xref>]. Therefore, cholesterol lowering induced by moderate aerobic exercise may have led to reduced leukocyte ROCK2 concentration. In addition, it has been reported that Lp(a) is also an important lipoprotein associated with inflammation and oxidation. Therefore, reduced Lp(a) level in the exercise group might also have contributed to the favorable change of NO production and ROCK2 expression. Last but not the least, increased NO concentration by moderate aerobic exercise could antagonize oxidative stress in one aspect, and in the other aspect, increased serum NO concentration reduced leukocyte infiltration and thereby mitigated inflammation, suppressed ROCK2 expression and protected DNA of endothelium from damage [<xref rid="cit0025" ref-type="bibr">25</xref>&#x02013;<xref rid="cit0027" ref-type="bibr">27</xref>].</p><p>There are several limitations of our study. First, although the data supported that moderate aerobic exercise was beneficial for lipid modification, endothelium protection and leukocyte ROCK2 concentration diminishment, the study is limited by its small scale and a short-term follow-up. Therefore, the data could not be used for inferring causality, but may be used for hypothesis generation, which is warranted for confirmation by future research. Second, since this was not a randomized study, so there was potential residual confounding which could not be adjusted. Third, the results from this study could not be generalized to other ethnic populations.</p><p>In conclusion, this study showed that in populations with newly diagnosed dyslipidemia, moderate aerobic exercise could favorably regulate cholesterol metabolism. Moreover, this kind of lifestyle modification is beneficial for improving endothelial function, which may be due to its effect on attenuating leukocyte ROCK2 concentration.</p></sec></body><back><ack><title>Acknowledgments</title><p>Huadong Bai and Jingchun Sun are co-first authors.</p><p>We greatly appreciate the help Dr. Wu Cong provided to improve the writing of our paper.</p><sec sec-type="COI-statement"><title>Conflict of interest</title><p>The authors declare no conflict of interest.</p></sec></ack><ref-list><title>References</title><ref id="cit0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weissberg</surname><given-names>PL</given-names></name><name><surname>Bennett</surname><given-names>MR</given-names></name></person-group><article-title>Atherosclerosis: an inflammatory disease</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><fpage>1928</fpage><lpage>9</lpage></element-citation></ref><ref id="cit0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forstermann</surname><given-names>U</given-names></name><name><surname>Munzel</surname><given-names>T</given-names></name></person-group><article-title>Endothelial nitric oxide synthase in vascular disease: from marvel to menace</article-title><source>Circulation</source><year>2006</year><volume>113</volume><fpage>1708</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">16585403</pub-id></element-citation></ref><ref id="cit0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonetti</surname><given-names>PO</given-names></name><name><surname>Lerman</surname><given-names>LO</given-names></name><name><surname>Lerman</surname><given-names>A</given-names></name></person-group><article-title>Endothelial dysfunction: a marker of atherosclerotic risk</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2003</year><volume>23</volume><fpage>168</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">12588755</pub-id></element-citation></ref><ref id="cit0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>MJ</given-names></name><name><surname>Cherng</surname><given-names>WJ</given-names></name><name><surname>Hung</surname><given-names>MY</given-names></name><etal/></person-group><article-title>Increased leukocyte Rho-associated coiled-coil containing protein kinase activity predicts the presence and severity of coronary vasospastic angina</article-title><source>Atherosclerosis</source><year>2012</year><volume>221</volume><fpage>521</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">22293227</pub-id></element-citation></ref><ref id="cit0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HW</given-names></name><name><surname>Liu</surname><given-names>PY</given-names></name><name><surname>Oyama</surname><given-names>N</given-names></name><etal/></person-group><article-title>Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/- mice</article-title><source>FASEB J</source><year>2008</year><volume>22</volume><fpage>3561</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">18556458</pub-id></element-citation></ref><ref id="cit0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>PY</given-names></name><name><surname>Chen</surname><given-names>JH</given-names></name><name><surname>Lin</surname><given-names>LJ</given-names></name><name><surname>Liao</surname><given-names>JK</given-names></name></person-group><article-title>Increased Rho kinase activity in a Taiwanese population with metabolic syndrome</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>49</volume><fpage>1619</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">17433952</pub-id></element-citation></ref><ref id="cit0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noma</surname><given-names>K</given-names></name><name><surname>Oyama</surname><given-names>N</given-names></name><name><surname>Liao</surname><given-names>JK</given-names></name></person-group><article-title>Physiological role of ROCKs in the cardiovascular system</article-title><source>Am J Physiol Cell Physiol</source><year>2006</year><volume>290</volume><fpage>C661</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16469861</pub-id></element-citation></ref><ref id="cit0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loirand</surname><given-names>G</given-names></name><name><surname>Sauzeau</surname><given-names>V</given-names></name><name><surname>Pacaud</surname><given-names>P</given-names></name></person-group><article-title>Small G proteins in the cardiovascular system: physiological and pathological aspects</article-title><source>Physiol Rev</source><year>2013</year><volume>93</volume><fpage>1659</fpage><lpage>720</lpage><pub-id pub-id-type="pmid">24137019</pub-id></element-citation></ref><ref id="cit0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name></person-group><article-title>Pathophysiological effects of RhoA and Rho-associated kinase on cardiovascular system</article-title><source>J Hypertens</source><year>2016</year><volume>34</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">26556565</pub-id></element-citation></ref><ref id="cit0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattori</surname><given-names>T</given-names></name><name><surname>Shimokawa</surname><given-names>H</given-names></name><name><surname>Higashi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>2234</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15096457</pub-id></element-citation></ref><ref id="cit0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nohria</surname><given-names>A</given-names></name><name><surname>Grunert</surname><given-names>ME</given-names></name><name><surname>Rikitake</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease</article-title><source>Circ Res</source><year>2006</year><volume>99</volume><fpage>1426</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">17095725</pub-id></element-citation></ref><ref id="cit0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfrum</surname><given-names>S</given-names></name><name><surname>Dendorfer</surname><given-names>A</given-names></name><name><surname>Rikitake</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2004</year><volume>24</volume><fpage>1842</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15319269</pub-id></element-citation></ref><ref id="cit0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandor</surname><given-names>B</given-names></name><name><surname>Nagy</surname><given-names>A</given-names></name><name><surname>Toth</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effects of moderate aerobic exercise training on hemorheological and laboratory parameters in ischemic heart disease patients</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e110751</fpage><pub-id pub-id-type="pmid">25347067</pub-id></element-citation></ref><ref id="cit0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazurek</surname><given-names>K</given-names></name><name><surname>Krawczyk</surname><given-names>K</given-names></name><name><surname>Zmijewski</surname><given-names>P</given-names></name><name><surname>Norkowski</surname><given-names>H</given-names></name><name><surname>Czajkowska</surname><given-names>A</given-names></name></person-group><article-title>Effects of aerobic interval training versus continuous moderate exercise programme on aerobic and anaerobic capacity, somatic features and blood lipid profile in collegate females</article-title><source>Ann Agric Environ Med</source><year>2014</year><volume>21</volume><fpage>844</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">25528932</pub-id></element-citation></ref><ref id="cit0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drenowatz</surname><given-names>C</given-names></name><name><surname>Sui</surname><given-names>X</given-names></name><name><surname>Fritz</surname><given-names>S</given-names></name><etal/></person-group><article-title>The association between resistance exercise and cardiovascular disease risk in women</article-title><source>J Sci Med Sport</source><year>2015</year><volume>18</volume><fpage>632</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">25311900</pub-id></element-citation></ref><ref id="cit0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meldrum</surname><given-names>DR</given-names></name><name><surname>Gambone</surname><given-names>JC</given-names></name><name><surname>Morris</surname><given-names>MA</given-names></name><name><surname>Esposito</surname><given-names>K</given-names></name><name><surname>Giugliano</surname><given-names>D</given-names></name><name><surname>Ignarro</surname><given-names>LJ</given-names></name></person-group><article-title>Lifestyle and metabolic approaches to maximizing erectile and vascular health</article-title><source>Int J Impot Res</source><year>2012</year><volume>24</volume><fpage>61</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">22072232</pub-id></element-citation></ref><ref id="cit0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boekholdt</surname><given-names>SM</given-names></name><name><surname>Hovingh</surname><given-names>GK</given-names></name><name><surname>Mora</surname><given-names>S</given-names></name><etal/></person-group><article-title>Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials</article-title><source>J Am Coll Cardiol</source><year>2014</year><volume>64</volume><fpage>485</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">25082583</pub-id></element-citation></ref><ref id="cit0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name></person-group><article-title>Rho-GTPase and atherosclerosis: pleiotropic effects of statins</article-title><source>J Am Heart Assoc</source><year>2015</year><volume>4</volume><fpage>e002113</fpage><pub-id pub-id-type="pmid">26124206</pub-id></element-citation></ref><ref id="cit0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>C</given-names></name><name><surname>Azcutia</surname><given-names>V</given-names></name><name><surname>Aikawa</surname><given-names>E</given-names></name><etal/></person-group><article-title>Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion</article-title><source>Eur Heart J</source><year>2013</year><volume>34</volume><fpage>615</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">22927557</pub-id></element-citation></ref><ref id="cit0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Etienne-Manneville</surname><given-names>S</given-names></name><name><surname>Hall</surname><given-names>A</given-names></name></person-group><article-title>Rho GTPases in cell biology</article-title><source>Nature</source><year>2002</year><volume>420</volume><fpage>629</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">12478284</pub-id></element-citation></ref><ref id="cit0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoneda</surname><given-names>A</given-names></name><name><surname>Multhaupt</surname><given-names>HA</given-names></name><name><surname>Couchman</surname><given-names>JR</given-names></name></person-group><article-title>The Rho kinases I and II regulate different aspects of myosin II activity</article-title><source>J Cell Biol</source><year>2005</year><volume>170</volume><fpage>443</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">16043513</pub-id></element-citation></ref><ref id="cit0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Mei</surname><given-names>Y</given-names></name><name><surname>Shoji</surname><given-names>T</given-names></name><etal/></person-group><article-title>Rho-associated coiled-coil-containing kinase 2 deficiency in bone marrow-derived cells leads to increased cholesterol efflux and decreased atherosclerosis</article-title><source>Circulation</source><year>2012</year><volume>126</volume><fpage>2236</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">23011471</pub-id></element-citation></ref><ref id="cit0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Noma</surname><given-names>K</given-names></name><etal/></person-group><article-title>FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2</article-title><source>FASEB J</source><year>2013</year><volume>27</volume><fpage>1439</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">23271052</pub-id></element-citation></ref><ref id="cit0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loprinzi</surname><given-names>PD</given-names></name><name><surname>Crespo</surname><given-names>CJ</given-names></name><name><surname>Andersen</surname><given-names>RE</given-names></name><name><surname>Smit</surname><given-names>E</given-names></name></person-group><article-title>Association of body mass index with cardiovascular disease biomarkers</article-title><source>Am J Prev Med</source><year>2015</year><volume>48</volume><fpage>338</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">25442230</pub-id></element-citation></ref><ref id="cit0025"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>DCA</given-names></name><name><surname>Montezano</surname><given-names>AC</given-names></name><name><surname>Burger</surname><given-names>D</given-names></name><name><surname>Touyz</surname><given-names>RM</given-names></name></person-group><article-title>Angiotensin II, NADPH oxidase, and redox signaling in the vasculature</article-title><source>Antioxid Redox Signal</source><year>2013</year><volume>19</volume><fpage>1110</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">22530599</pub-id></element-citation></ref><ref id="cit0026"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pokrywka</surname><given-names>A</given-names></name><name><surname>Zembron-Lacny</surname><given-names>A</given-names></name><name><surname>Baldy-Chudzik</surname><given-names>K</given-names></name><name><surname>Orysiak</surname><given-names>J</given-names></name><name><surname>Sitkowski</surname><given-names>D</given-names></name><name><surname>Banach</surname><given-names>M</given-names></name></person-group><article-title>The influence of hypoxic physical activity on cfDNA as a new marker of vascular inflammation</article-title><source>Arch Med Sci</source><year>2015</year><volume>11</volume><fpage>1156</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">26788076</pub-id></element-citation></ref><ref id="cit0027"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danese</surname><given-names>E</given-names></name><name><surname>Lippi</surname><given-names>G</given-names></name><name><surname>Sanchis-Gomar</surname><given-names>F</given-names></name><etal/></person-group><article-title>Physical exercise and DNA injury: good or evil?</article-title><source>Adv Clin Chem</source><year>2016</year><comment>in press</comment></element-citation></ref></ref-list></back></article>